Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04839965 · ClinicalTrials.gov registry record · Phase 2
Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen
A Phase 2 study, sponsored by Ampio Pharmaceuticals..
- Terminated
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT04839965 is a Phase 2 study that was terminated before completion, run by Ampio Pharmaceuticals.. The registered enrollment target is 36 participants.
The verdict
NCT04839965, a Phase 2 study, was terminated before completion, sponsored by Ampio Pharmaceuticals..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a Phase 2 randomized study to evaluate the safety and efficacy of IV Ampion in improving the clinical course and outcomes of adult COVID-19 patients requiring supplemental oxygen.
Interventions
- OTHER Saline
- BIOLOGICAL Ampion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-07-05 |
| Est. Completion | 2022-04-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04839965
The ClinicalTrials.gov registry entry for NCT04839965 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ampio Pharmaceuticals., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT04839965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04839965 about?
NCT04839965 is a clinical study titled "Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen". This is a Phase 2 randomized study to evaluate the safety and efficacy of IV Ampion in improving the clinical course and outcomes of adult COVID-19 patients requiring supplemental oxygen.
What is the current status of trial NCT04839965?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2021-07-05. Estimated completion is 2022-04-04.
What interventions are being tested in trial NCT04839965?
The interventions under investigation include: Saline (OTHER), Ampion (BIOLOGICAL).
Who is sponsoring clinical trial NCT04839965?
This trial is sponsored by Ampio Pharmaceuticals., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.